Skip to main content

SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December 11, 2025

Written by Customer Service on . Posted in Public Companies.

Press release – No.13 / 2025

SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December 11, 2025

Copenhagen, Denmark, September 11, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that it will host a Capital Markets Day in London on December 11, 2025, featuring presentations from management and external experts in obesity.

“Obesity is one of the greatest healthcare challenges of our time, and we are in the very early stages of a rapidly evolving market for weight loss therapies. With a differentiated pipeline targeting obesity and related comorbidities, strong partnerships supporting our leading programs, and a solid financial foundation, we are well positioned to realize our vision of becoming a key player in the future management of obesity.” said Adam Steensberg, President and Chief Executive Officer at Zealand Pharma.

“Zealand Pharma is now entering a catalyst-rich chapter from a position of strength. At our Capital Markets Day in December, we look forward to setting the stage for upcoming Phase 2 data with petrelintide and Phase 3 data with survodutide, while also sharing insights into our strategy on driving the next wave of innovation.”

External experts and thought leaders in the obesity field who will present alongside Zealand Pharma’s management team include Jonathan Roth, PhD, a metabolic researcher and pioneer in amylin-leptin biology; Dr. Louis Aronne, Professor of Clinical Medicine at Weill Cornell Medicine; and Dr. Carel Le Roux, Professor of Experimental Pathology at University College Dublin.

Further details regarding the time, venue, and registration logistics for investors and analysts wishing to participate in person will be provided in the coming weeks.

A live webcast will be available at https://www.zealandpharma.com/events/. A replay of the webcast will be archived on the company’s website following the presentation.

About Zealand Pharma
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.

Zealand Pharma was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand Pharma’s business and activities, please visit www.zealandpharma.com.

Contacts
Adam Lange (Investors)
Vice President, Investor Relations
Zealand Pharma
Email: alange@zealandpharma.com

Neshat Anis Ahmadi (Investors)
Investor Relations Manager
Zealand Pharma
Email: neahmadi@zealandpharma.com

Anna Krassowska, PhD (Investors and Media)
Vice President, Investor Relations & Corporate Communications
Zealand Pharma
Email: akrassowska@zealandpharma.com

Amber Fennell, Jessica Hodgson, Sean Leous (Media)
ICR Healthcare
ZealandPharma@icrhealthcare.com
+44 (0) 7739 658 783

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.